Literature DB >> 10326687

Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging.

I Songun1, C J van de Velde, J W Arends, P Blok, A J Grond, G J Offerhaus, J Hermans, J H van Krieken.   

Abstract

BACKGROUND: Due to the high variability of the epidemiology, genetics, morphology, and biologic behavior of gastric carcinoma, many classification systems are in use, e.g., the World Health Organization (WHO) classification; tumor differentiation; the criteria of Ming, Mulligan, and Laurén; and the recently introduced Goseki classification. In the authors' opinion, the TNM staging is the most valuable classification system, with a prognostic value for survival.
METHODS: To assess the reproducibility and usefulness of these systems in clinical practice, material from 285 gastric carcinoma patients entered in the Dutch Gastric Cancer Trial was analyzed by a panel of 5 experienced gastrointestinal pathologists. The presence of eosinophilic and lymphocytic infiltrates was analyzed in addition to the TNM staging.
RESULTS: Of the analyzed classification systems, only TNM stage, tumor differentiation, eosinophilic infiltrate, and the Goseki system contained information associated with the survival of patients with gastric carcinoma. The reproducibility was perfect for tumor differentiation (Kappa 1.00), nearly perfect for the WHO and Goseki classifications (Kappa 0.86 and 0.87, respectively), reasonably good for Laurén and lymphocytic infiltrate (Kappa 0.70), and reasonably good for eosinophilic infiltrate (Kappa 0.42).
CONCLUSIONS: Of all these systems, the Goseki classification was the only system with prognostic value that is additional to TNM staging.

Entities:  

Mesh:

Year:  1999        PMID: 10326687     DOI: 10.1002/(sici)1097-0142(19990515)85:10<2114::aid-cncr3>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Relationships between mucinous gastric carcinoma, MUC2 expression and survival.

Authors:  Emmanuelle Leteurtre; Farid Zerimech; Guillaume Piessen; Agnes Wacrenier; Xavier Leroy; Marie-Christine Copin; Christophe Mariette; Jean-Pierre Aubert; Nicole Porchet; Marie-Pierre Buisine
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

2.  Invasive squamous cell carcinoma of the eyelids and periorbital region.

Authors:  Hülya Gökmen Soysal; Fatma Markoç
Journal:  Br J Ophthalmol       Date:  2006-10-04       Impact factor: 4.638

3.  A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis.

Authors:  Enrico Solcia; Catherine Klersy; Luca Mastracci; Paola Alberizzi; Maria Elena Candusso; Marta Diegoli; Francesca Tava; Roberta Riboni; Rachele Manca; Ombretta Luinetti
Journal:  Virchows Arch       Date:  2009-08-12       Impact factor: 4.064

Review 4.  Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value.

Authors:  Felix Berlth; Elfriede Bollschweiler; Uta Drebber; Arnulf H Hoelscher; Stefan Moenig
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

5.  Histological grading in gastric cancer by Ming classification: correlation with histopathological subtypes, metastasis, and prognosis.

Authors:  Thomas Luebke; Stephan E Baldus; Guido Grass; Elfriede Bollschweiler; Jürgen Thiele; Hans-Peter Dienes; Arnulf H Hoelscher; Stefan P Moenig
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.282

6.  Prognostic value of Goseki histological classification in adenocarcinoma of the cardia.

Authors:  M G Fontana; M La Pinta; D Moneghini; V Villanacci; F Donato; G Rindi; S Paparini; C Baronchelli; G Bertoli; P Alquati
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

7.  Association between genetic polymorphisms in cortactin and susceptibility to gastric cancer.

Authors:  Dae Yong Kim; Joo Hyun Lee; Keun Young Kim; Dong Baek Kang; Won Cheol Park; Soo Cheon Chae; Jeong Kyun Lee
Journal:  Ann Surg Treat Res       Date:  2015-07-09       Impact factor: 1.859

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.